Pfizer (NYSE:PFE) Issues Earnings Results

Pfizer (NYSE:PFE) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04, FiscalAI reports. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the company posted $0.92 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer updated its FY 2026 guidance to 2.800-3.000 EPS.

Pfizer Trading Down 0.9%

NYSE PFE traded down $0.24 during trading on Tuesday, reaching $26.07. 10,815,908 shares of the stock traded hands, compared to its average volume of 42,342,914. Pfizer has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market cap of $148.21 billion, a price-to-earnings ratio of 19.13 and a beta of 0.35. The stock’s 50-day moving average price is $27.17 and its 200 day moving average price is $26.11.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s payout ratio is currently 126.47%.

Institutional Trading of Pfizer

Large investors have recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new position in Pfizer during the second quarter worth about $32,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $34,000. Birchwood Financial Partners Inc. bought a new position in shares of Pfizer during the 4th quarter valued at about $38,000. WFA of San Diego LLC bought a new position in shares of Pfizer during the 2nd quarter valued at about $40,000. Finally, Atlas Capital Advisors Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $41,000. Institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 earnings and revenue topped expectations, led by strong Eliquis sales and cancer-treatment growth. This is the primary driver behind the early upside in the stock. Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: FDA approved VEPPANU (vepdegestrant) for ESR1?mutated advanced breast cancer — a near?term pipeline win that can support long?term growth expectations. Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
• Positive Sentiment: Management highlighted growth from recently launched and acquired products (including Metsera acquisition) that are helping offset declines in legacy COVID products — a strategic positive for medium?term revenue diversification. Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
• Neutral Sentiment: Company formally reaffirmed its FY2026 guidance (EPS $2.80–3.00; revenue $59.5B–62.5B) in its press release — provides some clarity for the year but leaves room for execution risk. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
• Negative Sentiment: Guidance and some management commentary were interpreted as conservative — the FY EPS and revenue ranges sit at or slightly below consensus, which is weighing on sentiment despite the beat. PFE Earnings: Pfizer Stock Rises on Q1 Beat despite Lower 2026 Sales Outlook
• Negative Sentiment: Higher R&D spending reduced profit year?over?year and may continue to pressure margins in the near term; investors will watch how R&D investment converts to late?stage wins. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. Morgan Stanley raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Monday, March 2nd. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, Guggenheim boosted their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.74.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.